Skip to main content

Table 1 Association of IDO2 expression with clinicopathological characteristics of MTC

From: Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects

Characteristics

N (%)

P value

 

Total

Low IDO2 scores

High IDO2 scores

 

Gender

   

0.017 *

Male

85(45.5)

42(49.4)

43(50.6)

 

Female

102(54.5)

68(66.7)

34(33.3)

 

Age at surgery(year)

   

0.472

≤ 52

101(54.0)

57(56.4)

44(43.6)

 

>52

86(46.0)

53(61.6)

33(38.4)

 

Heredity

   

0.582

Hereditary

33(17.6)

18(54.5)

15(45.5)

 

sporadic

154(82.4)

92(59.7)

62(40.3)

 

Multifocal

   

0.038 *

Yes

55(29.4)

26(47.3)

29(52.7)

 

No

132(70.6)

84(63.6)

48(36.4)

 

ETE

   

0.020 *

Yes

76(40.6)

37(48.7)

39(51.3)

 

No

111(59.4)

73(65.8)

38(34.2)

 

Bilateral lesions

   

0.184

Yes

20(10.7)

9(45%)

11(55%)

 

No

167(89.3)

101(60.5)

66(39.5)

 

Tumor size(cm)

   

0.716

≤ 2

120(64.2)

73(60.8)

47(39.2)

 

2–4

57(30.5)

31(54.4)

26(45.6)

 

>4

10(5.3)

6(60.0)

4(40.0)

 

pT stage

   

0.004 *

T1/T2

108(57.7)

73(67.6)

35(32.4)

 

T3/T4

79(42.3)

37(46.8)

42(53.2)

 

pN stage

   

<0.001 *

N0

87(46.5)

73(83.9)

14(16.1)

 

N1a

26(13.9)

10(38.5)

16(61.5)

 

N1b

74(39.6)

27(36.5)

47(63.5)

 

8th TNM stage

   

<0.001 *

I/II

77(41.1)

63(81.8)

14(18.2)

 

III/IV

110(58.9)

47(42.7)

63(57.3)

 

Coexist HT

   

0.403

Yes

24(12.8)

16(66.7)

8(33.3)

 

No

163(87.2)

94(57.7)

69(42.3)

 

Pathology

   

0.319

Only MTC

105(56.1)

58(55.2)

47(44.8)

 

With adenomatous goiter

9(4.8)

6(66.7)

3(33.3)

 

With nodular goiter

51(27.3)

35(68.6)

16(31.4)

 

With PTC

22(11.8)

11(50.0)

11(50.0)

 

Recurrence

   

0.023 *

Yes

22(11.8)

8(36.4)

14(63.6)

 

No

165(88.2)

102(61.8)

63(38.2)

 

Biochemical cure

   

0.002 *

Yes

98(52.4)

68(69.4)

30(30.6)

 

No

89(47.6)

42(47.2)

47(52.8)

 
  1. *P<0.05; MTC, medullary thyroid carcinoma; IDO2, indoleamine 2,3-dioxygenase 2; ETE, extrathyroid extension; HT, Hashimoto’s thyroiditis